Anzeige
Mehr »
Mittwoch, 17.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
343 Leser
Artikel bewerten:
(1)

Ground-breaking OWise mobile app for prostate cancer patients launched in the UK today

LONDON, March 25, 2021 /PRNewswire/ -- Px, the digital health company dedicated to improving cancer patient experience and oncology outcomes, today announced the UK launch of its OWise mobile app platform for prostate cancer patients.

The OWise app has been co-designed with prostate cancer patients to support them with their treatment and life after diagnosis. Photo Credit: Beth Crockatt

In the UK, one in eight men will get prostate cancer during their lifetime. Data from 2019[1] show that following their diagnosis, 62% did not receive a care plan from their NHS providers, leaving many prostate cancer patients anxious and distressed.

On the back of its success of the award-winning, NHS accredited OWise breast cancer app, Px has developed, and co-designed with patients and clinicians, the OWise prostate cancer app and website to give patients personalised support from the first day of diagnosis.

OWise is a freely downloadable app that gives patients a range of personalised, self-management and shared decision-making tools to help them improve their wellbeing. It supports patients with customised, safe and reliable information based on the UK guidelines. By collating valuable insights about patients' day-to-day wellbeing OWise also assists medical teams in making informed decisions about on-going treatment.

OWise for prostate cancer has been positively received by both patients and clinicians.

Rob (64), prostate cancer patient, said, "This new app is a valuable addition for men with prostate cancer who want to record useful information about their cancer over time. OWise works on two levels and can be used as a simple record of events but is also an up-to-date source of information on prostate cancer and related problems. A bonus feature is the Decision Aid option which helps men work out which treatment might be best for them."

Professor Bhaskar Somani, Consultant Urological Surgeon at University Hospital Southampton, who is a widely published author on urology and technological innovation, commented, "A patient-facing app that empowers patients with the right information and shared decision-making tools at the right time, is exactly what was missing. OWise is a holistic solution that has the potential to transform how prostate cancer patients experience their diagnosis, treatment and follow-up."

For more information about OWise Prostate Cancer please visit www.owise.uk/prostate
watch this video: https://vimeo.com/516294047
or contact Px Founder and CEO Dr. Anne Bruinvels, at:
E-mail: anneb@pxhealthcare.com
Twitter: @owiseprostate | Facebook: https://www.facebook.com/owiseprostate

About Px HealthCare:
Px was established by medical scientists in 2012. The OWise breast cancer app was launched in the UK in 2016 on the back of its ongoing success in the Netherlands.

OWise was initially developed by Px founder, Dr. Anne Bruinvels. While Executive Director at the European Personalised Medicine Association, Anne realised that cancer patients' experience following diagnosis is poorer than it needs to be, and can be much improved when patients are correctly informed and supported during treatment and recovery.

Anne is a pharmacist by training and has a PhD in molecular neuroscience. She is joined in Px by her brother Dr. David Bruinvels, a clinical occupational physician specialising in oncology, and a team of 10 biomedical scientists, software developers and data scientists.

[1] National Cancer Patient Experience Survey 2019

Photo - https://mma.prnewswire.com/media/1473430/OWise_BethCrockatt_50.jpg

© 2021 PR Newswire
Epische Goldpreisrallye
Der Goldpreis hat ein neues Rekordhoch überschritten. Die Marke von 3.500 US-Dollar ist gefallen, und selbst 4.000 US-Dollar erscheinen nur noch als Zwischenziel.

Die Rallye wird von mehreren Faktoren gleichzeitig getrieben:
  • · massive Käufe durch Noten- und Zentralbanken
  • · Kapitalflucht in sichere Häfen
  • · hohe Nachfrage nach physisch besicherten Gold-ETFs
  • · geopolitische Unsicherheit und Inflationssorgen

Die Aktienkurse vieler Goldproduzenten und Explorer sind in den vergangenen Wochen regelrecht explodiert.

Doch es gibt noch Titel, die Nachholpotenzial besitzen. In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Goldaktien jetzt besonders aussichtsreich sind und warum der Aufwärtstrend noch lange nicht vorbei sein dürfte.

Laden Sie jetzt den Spezialreport kostenlos herunter und profitieren Sie von der historischen Gold-Hausse.

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.